All members of the Expert Panel complied with the American Society of Clinical Oncology (ASCO) policy on conflicts of interest, which requires disclosure of any financial or other interest that might be construed as constituting an actual, potential, or apparent conflict. Members of the expert Panel completed ASCO's disclosure form and were asked to reveal ties to companies with products that might be affected by promulgation of the guidelines. Information was requested regarding employment, consultancies, stock ownership, honoraria, research funding, expert testimony, and membership on company advisory committees. The Panel made decisions on a case-by-case basis as to whether an individual's role should be limited as a result of a conflict. No limiting conflicts were identified.
Note: Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors in the original journal of publication.
Employment or Leadership Position: None Consultant or Advisory Role: David R. Spigel, Genentech (C); Frances A. Shepherd, Pierre Fabre (C), GlaxoSmithKline (C)
Stock Ownership: None Honoraria: Peter M. Ellis, Bristol-Myers Squibb; Frances A. Shepherd, Pierre Fabre, GlaxoSmithKline Research Funding: Christopher G. Azzoli, Genentech Biooncology, Sanofi-aventis, Allos Therapeutics; David R. Spigel, Genentech, Sanofi-aventis Expert Testimony: None Other Remuneration: None
